2,6-Lutidine → (S)-N-[5-((S)-2,2-dimethyl-[1,3]dioxolan-4-yl)-pyrazin-2-yl]-4-methylsulfanyl-2-(1-oxo-4-trifluoromethyl-1,3-dihydro-isoindol-2-yl)-butyramide

HRID 1261508

Reaktionsgleichung

Reaktionsgleichung von HRID 1261508
[CH3:1][S:2][CH2:3][CH2:4][C@H:5]([N:9]1[CH2:17][C:16]2[C:11](=[CH:12][CH:13]=[CH:14][C:15]=2[C:18]([F:21])([F:20])[F:19])[C:10]1=[O:22])[C:6](O)=[O:7].C(Cl)(=O)C(Cl)=O.[CH3:29][C:30]1([CH3:42])[O:34][C@@H:33]([C:35]2[N:36]=[CH:37][C:38]([NH2:41])=[N:39][CH:40]=2)[CH2:32][O:31]1.N1C(C)=CC=CC=1C>C(Cl)Cl.CN(C)C=O.CO>[CH3:29][C:30]1([CH3:42])[O:34][C@@H:33]([C:35]2[N:36]=[CH:37][C:38]([NH:41][C:6](=[O:7])[C@@H:5]([N:9]3[CH2:17][C:16]4[C:11](=[CH:12][CH:13]=[CH:14][C:15]=4[C:18]([F:20])([F:19])[F:21])[C:10]3=[O:22])[CH2:4][CH2:3][S:2][CH3:1])=[N:39][CH:40]=2)[CH2:32][O:31]1

Komponenten

8

Edukt 4

HCID 79372,6-LutidineHCID 65578Oxalyl chlorideHCID 533755855-((S)-2,2-dimethyl-[1,3]dioxolan-4-yl)-pyrazin-2-ylamineHCID 70944912(S)-4-methylsulfanyl-2-(1-oxo-4-trifluoromethyl-1,3-dihydro-isoindol-2-yl)-butyric acid

Produkt 1

HCID 70945445(S)-N-[5-((S)-2,2-dimethyl-[1,3]dioxolan-4-yl)-pyrazin-2-yl]-4-methylsulfanyl-2-(1-oxo-4-trifluoromethyl-1,3-dihydro-isoindol-2-yl)-butyramideAusbeute 32,3 %

Reagenzien, Katalysatoren, Lösungsmittel 3

HCID 6228DimethylformamideKatalysatorHCID 887MethanolLösungsmittelHCID 6344DichloromethaneLösungsmittel3×

Versuchsvorschrift

A solution of (S)-4-methylsulfanyl-2-(1-oxo-4-trifluoromethyl-1,3-dihydro-isoindol-2-yl)-butyric acid (57 mg, 0.17 mmol) in methylene chloride (5 mL) and N,N-dimethylformamide (3 drops) at room temperature was treated with a solution of oxalyl chloride (2.0M in methylene chloride, 210 μL, 0.34 mmol) and stirred for 15 min. After this time, the reaction mixture was concentrated in vacuo and then diluted with methylene chloride (5 mL) and added to a flask containing a solution of 5-((S)-2,2-dimethyl-[1,3]dioxolan-4-yl)-pyrazin-2-ylamine (prepared as in WO2004052869, Example 54, 67 mg, 0.34 mmol), 2,6-lutidine (64 μL, 0.34 mmol) in methylene chloride (2.5 mL) at room temperature. The reaction mixture was then stirred at room temperature for a period of 2 h. After this time, the reaction mixture was treated with methanol and then diluted with methylene chloride. The reaction mixture was then transferred to a separatory funnel and washed with a 1N aqueous hydrochloric acid solution. The organic layer was then dried over magnesium sulfate, filtered to remove the drying agent and the filtrate was concentrated with silica gel (2 g). The silica gel with absorbed material was placed in a SIM and purified via Biotage flash column chromatography (40 S silica gel column, 40%-60% ethyl acetate/hexanes) to afford (S)—N-[5-((S)-2,2-dimethyl-[1,3]dioxolan-4-yl)-pyrazin-2-yl]-4-methylsulfanyl-2-(1-oxo-4-trifluoromethyl-1,3-dihydro-isoindol-2-yl)-butyramide (28 mg, 32%) as a colorless sticky solid.

Aufarbeitung

  1. concentrationAfter this time, the reaction mixture was concentrated in vacuo
  2. additiondiluted with methylene chloride (5 mL)
  3. additionadded to a flask
  4. stirringThe reaction mixture was then stirred at room temperature for a period of 2 h
  5. customThe reaction mixture was then transferred to a separatory funnel
  6. washwashed with a 1N aqueous hydrochloric acid solution
  7. dry with materialThe organic layer was then dried over magnesium sulfate
  8. filtrationfiltered
  9. customto remove the drying agent
  10. concentrationthe filtrate was concentrated with silica gel (2 g)
  11. custompurified via Biotage flash column chromatography (40 S silica gel column, 40%-60% ethyl acetate/hexanes)

Quellen und Nachweise

ORD-Eintrag
ord-3ee5ec7298bc414f93156f9ff771acc4
Quelldatensatz
uspto-grants-2013_06
Patentnummer
US08470866B2

Verknüpfte Notizen

Wird geladen…